These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20229082)

  • 1. Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
    Appels NM; Bolijn MJ; van Eijndhoven MA; Stephens TC; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):137-45. PubMed ID: 20229082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
    Zhou S
    Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
    Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
    Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.
    Buser CA; Dinsmore CJ; Fernandes C; Greenberg I; Hamilton K; Mosser SD; Walsh ES; Williams TM; Koblan KS
    Anal Biochem; 2001 Mar; 290(1):126-37. PubMed ID: 11180946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.
    Cengel KA; Deutsch E; Stephens TC; Voong KR; Kao GD; Bernhard EJ
    Cancer Biol Ther; 2006 Sep; 5(9):1206-10. PubMed ID: 16969121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
    Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
    Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF; Qian Y; Vogt A; Hamilton AD; Sebti SM
    J Biol Chem; 1996 Nov; 271(44):27402-7. PubMed ID: 8910319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
    Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
    Maiello MR; D'Alessio A; De Luca A; Carotenuto A; Rachiglio AM; Napolitano M; Cito L; Guzzo A; Normanno N
    Breast Cancer Res Treat; 2007 May; 102(3):275-82. PubMed ID: 17004112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of inhibition of farnesylation and geranylgeranylation on renal fibrogenesis in vitro.
    Masterson R; Kelynack K; Hewitson T; Becker G
    Nephron Exp Nephrol; 2006; 102(1):e19-29. PubMed ID: 16179803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of potential markers of farnesyltransferase inhibition.
    Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
    Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.